These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 11059258)

  • 1. [Pharmacokinetics of second generation antidepressants].
    Grzesiak M; Beszłej JA; Kiejna A
    Psychiatr Pol; 2000; 34(4):577-94. PubMed ID: 11059258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinically relevant drug interactions with new generation antidepressants and antipsychotics].
    Eckert A
    Ther Umsch; 2009 Jun; 66(6):485-92. PubMed ID: 19496045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of the newest antidepressants: comparisons with related predecessors.
    Caccia S
    IDrugs; 2004 Feb; 7(2):143-50. PubMed ID: 15057659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidepressant drugs in the elderly--role of the cytochrome P450 2D6.
    Vandel P
    World J Biol Psychiatry; 2003 Apr; 4(2):74-80. PubMed ID: 12692778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
    Lynch T; Price A
    Am Fam Physician; 2007 Aug; 76(3):391-6. PubMed ID: 17708140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic considerations of antidepressant use in the elderly.
    DeVane CL; Pollock BG
    J Clin Psychiatry; 1999; 60 Suppl 20():38-44. PubMed ID: 10513858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients.
    Vandel P; Haffen E; Nezelof S; Broly F; Kantelip JP; Sechter D
    Hum Psychopharmacol; 2004 Jul; 19(5):293-8. PubMed ID: 15252821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics-guided dose modifications of antidepressants.
    Seeringer A; Kirchheiner J
    Clin Lab Med; 2008 Dec; 28(4):619-26. PubMed ID: 19059066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects.
    Brockmöller J; Meineke I; Kirchheiner J
    Clin Pharmacol Ther; 2007 May; 81(5):699-707. PubMed ID: 17329996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocytes--the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo.
    Gómez-Lechón MJ; Castell JV; Donato MT
    Chem Biol Interact; 2007 May; 168(1):30-50. PubMed ID: 17134688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug interaction in psycho-oncology: antidepressants and antineoplastics.
    Miguel C; Albuquerque E
    Pharmacology; 2011; 88(5-6):333-9. PubMed ID: 22123153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.
    Rau T; Wohlleben G; Wuttke H; Thuerauf N; Lunkenheimer J; Lanczik M; Eschenhagen T
    Clin Pharmacol Ther; 2004 May; 75(5):386-93. PubMed ID: 15116051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bench to bedside: Pharmacogenomics, adverse drug interactions, and the cytochrome P450 system.
    Sikka R; Magauran B; Ulrich A; Shannon M
    Acad Emerg Med; 2005 Dec; 12(12):1227-35. PubMed ID: 16282513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome P450 pharmacogenetics and cancer.
    Rodriguez-Antona C; Ingelman-Sundberg M
    Oncogene; 2006 Mar; 25(11):1679-91. PubMed ID: 16550168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic monitoring of tricyclic antidepressant drugs].
    Grzesiak M; Beszłej JA; Szewczuk-Bogusławska M
    Psychiatr Pol; 2003; 37(5):825-37. PubMed ID: 14631602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions.
    Greenblatt DJ; von Moltke LL; Harmatz JS; Shader RI
    J Clin Psychopharmacol; 1999 Oct; 19(5 Suppl 1):23S-35S. PubMed ID: 10507506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. II. Participation of CYP isoenzymes in the metabolism of endogenous substances and drugs.
    Tomaszewski P; Kubiak-Tomaszewska G; Pachecka J
    Acta Pol Pharm; 2008; 65(3):307-18. PubMed ID: 18646550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Retrospective assessment of the antidepressants tolerance in the group of patients with diagnosis of depression and different CYP2D6 genotype].
    Grzesiak M; Beszłej A; Lebioda A; Jonkisz A; Dobosz T; Kiejna A
    Psychiatr Pol; 2003; 37(3):433-44. PubMed ID: 13677973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bupropion: pharmacology and therapeutic applications.
    Foley KF; DeSanty KP; Kast RE
    Expert Rev Neurother; 2006 Sep; 6(9):1249-65. PubMed ID: 17009913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.